接受非增强整合酶抑制剂方案且病毒抑制的HIV跨性别女性与口服雌二醇的无HIV跨性别女性雌二醇浓度比较:一项先导研究
这项单中心、平行组、横断面先导研究比较了8名接受非增强整合酶链转移抑制剂(INSTI)方案且病毒抑制的HIV跨性别女性与7名无HIV跨性别女性口服雌二醇后的血清雌二醇浓度。所有时间点两组雌二醇浓度均无显著差异,11名(73%)参与者在服药后4小时达到目标范围200-735 pmol/L。作者认为提示FHT与非增强INSTI方案之间临床相关药物相互作用概率较低。
要点
- 两组雌二醇浓度在所有检测时间点均无显著差异。
- 11名(73%)参与者在服药后4小时雌二醇浓度在200-735 pmol/L范围内。
- 作者认为FHT与非增强INSTI方案之间临床相关药物相互作用概率较低。
核心结论
- HIV跨性别女性与无HIV跨性别女性的雌二醇浓度无统计学差异,提示FHT与非增强INSTI方案之间临床相关药物相互作用概率较低。
研究设计与样本
- 单中心、平行组、横断面先导研究,纳入8名HIV跨性别女性和7名无HIV跨性别女性。
- 纳入年龄≥18岁、每日口服雌二醇≥2 mg至少3个月并联合抗雄激素的跨性别女性;HIV感染者需接受抑制性ART≥3个月。
- 在服药前及服药后2、4、6、8小时测量血清雌二醇浓度,使用Wilcoxon秩和检验比较组间中位数。
主要发现
- 参与者中位年龄32岁(IQR:28,39),中位口服雌二醇剂量4 mg(范围2-6 mg),中位FHT使用时间4年(IQR:2,8)。
- 8名HIV跨性别女性中6名使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺,2名使用多替拉韦/阿巴卡韦/拉米夫定。
- 所有雌二醇浓度在两组间均无显著差异。
- 11名(73%)参与者在服药后4小时雌二醇浓度在200-735 pmol/L范围内(HIV组75%,无HIV组71%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Feminizing hormone therapy (FHT) is essential to many trans women. Concern about negative drug interactions between FHT and ART can be an ART adherence barrier among trans women with HIV. OBJECTIVES: In this single-centre, parallel group, cross-sectional pilot study, we measured serum oestradiol concentrations in trans women with HIV taking FHT and unboosted integrase strand transfer inhibitor (INSTI)-based ART versus trans women without HIV taking FHT. METHODS: We included trans women with and without HIV, aged ≥18 years, taking ≥2 mg/day of oral oestradiol for at least 3 months plus an anti-androgen. Trans women with HIV were on suppressive ART ≥3 months. Serum oestradiol concentrations were measured prior to medication dosing and 2, 4, 6 and 8 h post-dose. Median oestradiol concentrations were compared between groups using Wilcoxon rank-sum tests. RESULTS: Participants (n = 8 with HIV, n = 7 without) had a median age of 32 (IQR: 28, 39) years. Among participants, the median oral oestradiol dose was 4 mg (range 2-6 mg). Participants had been taking FHT for a median of 4 years (IQR: 2, 8). Six trans women with HIV were taking bictegravir/emtricitabine/tenofovir alafenamide and two were taking dolutegravir/abacavir/lamivudine. All oestradiol concentrations were not significantly different between groups. Eleven (73%) participants had target oestradiol concentrations in the range 200-735 pmol/L at C4h (75% among women with HIV, 71% among those without HIV). CONCLUSIONS: Oestradiol concentrations were not statistically different in trans women with HIV compared with those without HIV, suggesting a low probability of clinically relevant drug-drug interactions between FHT and unboosted INSTI-based ART.
引用
- Loutfy M, Lacombe-Duncan A, Tseng A, et al. Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study. J Antimicrob Chemother. 2023. PMID: 37681452. doi:10.1093/jac/dkad270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。